Novo Nordisk and Anthropic today announced a collaboration that will help Novo accelerate the development of new medicines and advance AI-driven software development.     
The companies will jointly address key drug discovery challenges identified by scientists and computational teams at Novo, develop targeted solutions for specific scientific challenges and workflows to support biological reasoning, and help accelerate the discovery and development of new medicines.
“This partnership is another testament to our ambition to become the world’s most AI-driven healthcare company, building on Novo's current AI initiatives with other technology partners. Joining forces with Anthropic will supercharge our R&D organisation and help us on our mission to bring new, transformative health solutions to people living with chronic diseases,“ said Mike Doustdar, president and CEO of Novo. “AI can help us increase productivity in R&D and compress the path from research to marketed product. But beyond this, AI tools can also offer completely new scientific opportunities and aid reasoning and understanding of human biology and drug mechanics.”